IRCT20200727048226N1
Not yet recruiting
Phase 2
Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary artery
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- acute myocardial infarction.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 88
- Status
- Not yet recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •non\-diabetic patients with PPCI on LAD that are SVD: non\-diabetic patients definition: 1\-HbA1C\<6\.5 2\-history of non\-diabetes 3\-twice FBS\<100 if two of three of these exist patient is eligible for entery of trial
Exclusion Criteria
- •1\-History of serious hypersensitivity to empagliflozin or any component of the formulation; \-Severe renal impairment (eGFR \<30 mL/minute/1\.73 m2\), end\-stage renal disease (ESRD), or dialysis 2\-patients that have more than one vessel disease or have SVD with non\-culprit lesion \>70% or with SVD of LCX or RCA 3\-patients 4\- diabetic patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Impact of Empagliflozin on heart in patients with myocardial infarctioMyocardial infarctionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-004591-22-ATMedical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology476
Active, not recruiting
Phase 1
Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure)EUCTR2017-002695-45-DERWTH Aachen University represented by the Rector, himself, represented by the Dean of the Medical Faculty50
Completed
Not Applicable
Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized TrialType 2 diabetes with acute myocardial infarctionJPRN-UMIN000030158ippon Medical School Hospital98
Completed
Phase 4
Empagliflozin and its effect on heart failure in type 2 diabetesE11I50.9Type 2 diabetes mellitusHeart failure, unspecifiedDRKS00009894niversitätsklinikum Freiburg Abteilung Endokrinologie und Diabetologie72
Active, not recruiting
Phase 1
Empagliflozin and its effect on heart failure in type 2 diabetesEUCTR2016-000214-30-DEniversitätsklinikum Freiburg270